Showing results (1401-1410 of 1,421) with videos related to

Sort By:
Pageof 143
Plos One|June 22, 2018
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignanciesHolly Koblish, Yun-Long Li, Niu Shin, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2011
Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonistChangsheng Zheng, Ganfeng Cao, Michael Xia, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 ActivityChu-Biao Xue, Lihua Chen, Ganfeng Cao, et al.
Journal of Neurosurgery|February 20, 2026
Pallidus internus versus subthalamic nucleus deep brain stimulation for Meige syndrome: a randomized, controlled, double-blind multicenter trialYang Wu, Hai-Bo Ren, Bo-Tao Xiong, et al.
Environmental Science and Pollution Research International|August 27, 2021
Associations between lung-deposited dose of particulate matter and culture-positive pulmonary tuberculosis pleurisyKuan-Jen Bai, Nguyen Thanh Tung, Ta-Chih Hsiao, et al.
Hepatology (Baltimore, Md.)|March 5, 2025
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort studyBeat Moeckli, Charles-Henri Wassmer, Sofia El Hajji, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)Eddy W Yue, Yun-Long Li, Brent Douty, et al.
Nucleic Acids Research|September 2, 2016
Molecular signatures associated with ZIKV exposure in human cortical neural progenitorsFeiran Zhang, Christy Hammack, Sarah C Ogden, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 AntagonistChu-Biao Xue, Hao Feng, Ganfeng Cao, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 AntagonistChu-Biao Xue, Anlai Wang, Qi Han, et al.
Pageof 143